Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Combination With Ipilimumab and Nivolumab in Advanced Melanoma, NSCLC, or Urothelial Carcinoma
NCT04940299Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in melanoma, non-small cell lung cancer (NSCLC) and urothelial carcinoma (UC) (3 cohorts), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Incidence of dose limiting toxicity at 2 years and Occurrence of one or more grade 3 or higher adverse event at 2 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04940299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940299.